The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Objective: To review drug interaction studies of glucagon-like ... needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

GLP-1 drugs, or GLP-1 receptor agonists, were originally solely intended for use as diabetes medications. However, they are now being used for a variety of purposes, including helping people with ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Meanwhile, Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations. "Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...